Breakthrough Therapies in Dermatology Management – Advances in Atopic Dermatitis for Managed Care and Payer Professionals – Case Study 2

Expert Faculty Author:

John Fox, MD, MHA
Chief Boundary Spanner
Foxworthy Healthcare Consulting, PLLC
Click here for biography

Adam Friedman, MD, FAAD
Professor and Chair of Dermatology
Associate Residency Program Director
Director of Translational Research
Director of Supportive Oncodermatology
Department of Dermatology
George Washington School of Medicine and Health Sciences
Click here for biography

Edmund Pezalla, MD, MPH
Enlightenment Bioconsult, LLC
Click here for biography

Target Audience
The primary target audience for this initiative consists of medical directors, registered nurses, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.

Statement of Need/Program Overview
The evolving AD treatment landscape accentuates the need for increased disease and therapeutic knowledge amongst managed care, specialty pharmacy, and other payer professionals to provide enhanced clinical and economic outcomes to beneficiaries with AD. In addition, payer decision makers need instruction on benefit design strategies that can support an improvement in overall outcomes in patients with AD.

Educational Objectives

Accreditation Information

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine, National Eczema Association, and Impact Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA4008162-9999-22-042-H01-P
Type of ActivityKnowledge

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Name of Faculty or Presenter

Reported Financial Relationship

John Fox, MD, MHA

John Fox, MD, MHA has nothing to disclose.

Adam Friedman, MD, FAAD

Consulting fees (e.g. advisory boards) –  Sanova Works, Amgen, La Roche-Posay Laboratorie Pharmaceutique, Galderma USA, Pfizer, Biogen, Valeant Pharmaceuticals North America LLC, Intraderm Pharmaceuticals, Oculus Innovative Science, Inc., Novartis, Johnson and Johnson Consumer Products Company, Encore Dermatology, Inc., Exeltis, Promius Pharma, LLC., Eli Lilly and Company, Derrmira, Menlo Therapeutics, Ortho Dermatologics, Hoth Therapeutics, Greenway Therapeutix, Brickell Biotech, Inc.

Edmund Pezalla, MD, MPH

Consulting fees (e.g. advisory boards) – Pfizer, Sanofi Genzyme, Regeneron

The PIM planners and managers have nothing to disclose.
The NEA planners and managers have nothing to disclose.
The Impact Education, LLC® planners and managers have nothing to disclose.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

In order to obtain your CE certificate, please follow the steps below at the conclusion of the activity:

  1. Complete the evaluation form
  2. For ACCME and ANCC accreditation, a CE certificate will be made available immediately to download and print.

For Pharmacists: Upon successfully completing the activity evaluation, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account. Credit must be uploaded to CPE Monitor within 30 days.

There is no fee for this educational activity.